BACKGROUND AND OBJECTIVES: The mutational status of the immunoglobulin heavy chain variable region genes (IGVH) is a strong indicator of prognosis in B-cell chronic lymphocytic leukaemia (CLL). Since the determination of the IGVH mutation status is very labor-intensive, alternative prognostically relevant markers would facilitate CLL diagnostics. DESIGN AND METHODS: Ten genes were selected from previously published gene expression profiling studies based on their differential expression in IGVH mutated versus unmutated cases of CLL, and tested with real-time quantitative polymerase chain reaction (RQ-PCR) in unpurified samples from 130 CLL patients. To ascertain potential contaminating effects by normal hematopoietic cells, the expression levels of the selected genes were determined in normal monocytes, B cells, T cells, NK cells and granulocytes. RESULTS: The selected genes, i.e., ZAP70, LPL, SPG20, ADAM29, NRIP1, AKAP12, DMD, SEPT10, TPM2 and CLECSF2, showed prognostic significance. In multivariate logistic regression analysis expression levels of LPL, ZAP70, ADAM29 and SEPT10 were the most predictive for IGVH mutational status. In univariate analysis the expression of LPL was the best predictor. For survival, expression of LPL was the strongest prognostic factor. In combination with the three cytogenetic markers associated with a poor prognosis, i.e., deletions 17p13, 11q22 and trisomy 12, expression of LPL and IGVH mutational status performed equally well with regard to their predictive value for survival, both being more predictive than ZAP70. INTERPRETATION AND CONCLUSIONS: This study demonstrates that LPL expression is a predictor for survival in CLL, and for this purpose is as good as IGVH mutational status and more reliable than ZAP70 expression when tested in unpurified CLL samples.
BACKGROUND AND OBJECTIVES: The mutational status of the immunoglobulin heavy chain variable region genes (IGVH) is a strong indicator of prognosis in B-cell chronic lymphocytic leukaemia (CLL). Since the determination of the IGVH mutation status is very labor-intensive, alternative prognostically relevant markers would facilitate CLL diagnostics. DESIGN AND METHODS: Ten genes were selected from previously published gene expression profiling studies based on their differential expression in IGVH mutated versus unmutated cases of CLL, and tested with real-time quantitative polymerase chain reaction (RQ-PCR) in unpurified samples from 130 CLL patients. To ascertain potential contaminating effects by normal hematopoietic cells, the expression levels of the selected genes were determined in normal monocytes, B cells, T cells, NK cells and granulocytes. RESULTS: The selected genes, i.e., ZAP70, LPL, SPG20, ADAM29, NRIP1, AKAP12, DMD, SEPT10, TPM2 and CLECSF2, showed prognostic significance. In multivariate logistic regression analysis expression levels of LPL, ZAP70, ADAM29 and SEPT10 were the most predictive for IGVH mutational status. In univariate analysis the expression of LPL was the best predictor. For survival, expression of LPL was the strongest prognostic factor. In combination with the three cytogenetic markers associated with a poor prognosis, i.e., deletions 17p13, 11q22 and trisomy 12, expression of LPL and IGVH mutational status performed equally well with regard to their predictive value for survival, both being more predictive than ZAP70. INTERPRETATION AND CONCLUSIONS: This study demonstrates that LPL expression is a predictor for survival in CLL, and for this purpose is as good as IGVH mutational status and more reliable than ZAP70 expression when tested in unpurified CLL samples.
Authors: Shih-Shih Chen; Rainer Claus; David M Lucas; Lianbo Yu; Jiang Qian; Amy S Ruppert; Derek A West; Katie E Williams; Amy J Johnson; Fred Sablitzky; Christoph Plass; John C Byrd Journal: Blood Date: 2010-11-22 Impact factor: 22.113
Authors: Lynne V Abruzzo; Lynn L Barron; Keith Anderson; Rachel J Newman; William G Wierda; Susan O'brien; Alessandra Ferrajoli; Madan Luthra; Sameer Talwalkar; Rajyalakshmi Luthra; Dan Jones; Michael J Keating; Kevin R Coombes Journal: J Mol Diagn Date: 2007-08-09 Impact factor: 5.568
Authors: Mohd Arifin Kaderi; Meena Kanduri; Anne Mette Buhl; Marie Sevov; Nicola Cahill; Rebeqa Gunnarsson; Mattias Jansson; Karin Ekström Smedby; Henrik Hjalgrim; Jesper Jurlander; Gunnar Juliusson; Larry Mansouri; Richard Rosenquist Journal: Haematologica Date: 2011-04-20 Impact factor: 9.941
Authors: Nancy B Kuemmerle; Evelien Rysman; Portia S Lombardo; Alison J Flanagan; Brea C Lipe; Wendy A Wells; Jason R Pettus; Heather M Froehlich; Vincent A Memoli; Peter M Morganelli; Johannes V Swinnen; Luika A Timmerman; Leila Chaychi; Catherine J Fricano; Burton L Eisenberg; William B Coleman; William B Kinlaw Journal: Mol Cancer Ther Date: 2011-01-31 Impact factor: 6.261
Authors: Zoltán Mátrai; Hajnalka Andrikovics; Anikó Szilvási; András Bors; András Kozma; Emma Ádám; Gabriella Halm; Éva Karászi; Attila Tordai; Tamás Masszi Journal: Pathol Oncol Res Date: 2016-10-18 Impact factor: 3.201
Authors: Eloisa Jantus Lewintre; Cristina Reinoso Martín; Carlos García Ballesteros; David Montaner; Rosa Farrás Rivera; José Ramón Mayans; Javier García-Conde Journal: Haematologica Date: 2009-02 Impact factor: 9.941